Unidentified Speaker 4 outlined Bill 859 as "an act relating to psychedelic therapy and clinical drug development trials," saying the measure would recreate and empower the prior advisory working group and explore a partnership with a 13-state consortium led by Texas to pursue FDA clinical trials. Speaker 4 framed the bill as study and trial-enabling rather than legalization: "the bill does not legalize psychedelic medicines... it has the board explore ways to safely implement clinical trials in Vermont."
Sponsor context and testimony: Speaker 4 described receiving personal benefit from Ibogaine and said some Vermonters have experienced dramatic improvements. The sponsor recommended careful, regulated clinical trials and suggested that the Human Services committee could take the bill if capacity exists; the sponsor also offered an option to remove direct settlement funding and ask the Opioid Settlement/OSAC committee to consult with the psychedelic board and return with investment recommendations.
Funding and timing: Members flagged a $300,000 opioid settlement reference and discussed whether that money should be used directly in the bill. Speaker 4 proposed removing the settlement allocation and instead having OSAC and the advisory board produce financing recommendations, to avoid controversy and allow planning to proceed.
Why it matters: The bill would position Vermont to participate in multi-state clinical trials, potentially giving some Vermonters access to emerging therapies for severe depression, PTSD and addiction. Members stressed that trial infrastructure, regulatory safeguards and intercommittee coordination (Human Services vs. Health Care) will matter for any practical steps.
Next steps: Chair agreed to check Human Services' capacity and to consult witnesses to streamline testimony if the bill is docketed; members discussed the option of studying the clinical-trial component further if it proved too controversial for immediate action.